Congressional Oversight “Misunderstood” By Von Eschenbach – Grassley
This article was originally published in The Tan Sheet
Executive Summary
Continued criticism of FDA Acting Commissioner Andrew von Eschenbach by Senate Finance Committee Chairman Charles Grassley (R-Iowa) suggests that chances of a Senate vote on the nominee as full commissioner during Congress' lame-duck session have not brightened
You may also be interested in...
Releasing IoM Drug Safety Report Could Be Early On Von Eschenbach’s Watch
One of Andrew von Eschenbach's first major steps as FDA commissioner will likely be a release of the agency task force response to the Institute of Medicine's (IoM) recommendations to improve drug safety oversight
Releasing IoM Drug Safety Report Could Be Early On Von Eschenbach’s Watch
One of Andrew von Eschenbach's first major steps as FDA commissioner will likely be a release of the agency task force response to the Institute of Medicine's (IoM) recommendations to improve drug safety oversight
Releasing IoM Drug Safety Report Could Be Early On Von Eschenbach’s Watch
One of Andrew von Eschenbach's first major steps as FDA commissioner will likely be a release of the agency task force response to the Institute of Medicine's (IoM) recommendations to improve drug safety oversight